Hypoxia Exacerbation-Triggered Doxorubicin Prodrug Activation for Sequential Photodynamic/Chemotherapy
Source abstract
Abstract
Hypoxia, which can promote tumor invasiveness and metastasis, is a major obstacle to various cancer therapies. At the same time, the hypoxic tumor microenvironment provides a great target for achieving precise treatment. Here, we report a nanoprodrug consisting of a hypoxia-responsive doxorubicin prodrug and a pH-responsive photosensitizer-containing amphiphilic polymer. When the nanoprodrug accumulates in tumor cells, the acidic environment promotes the disintegration of the nanoprodrug, which is beneficial for improving the generation efficiency of singlet oxygen and activating prodrugs. Under 660 nm laser irradiation, the photodynamic therapy process consumes oxygen and produces toxic singlet oxygen. The hypoxia exacerbation further promotes activation of the doxorubicin prodrug. Therefore, this study provides a promising approach to achieve great therapeutic efficacy by sequential photodynamic/chemotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin 300072, China
Funding
China Postdoctoral Science Foundation · Young Elite Scientists Sponsorship Program by Tianjin · National Natural Science Foundation of China · China Postdoctoral Science Foundation - Tianjin Joint Support Program · Postdoctoral Fellowship Program of CPSF
References (41)
Show source-provided references
1. 10.1021/acsami.8b0649110.1021/acsami.8b06491 ↗
2. 10.1016/j.bbrc.2020.09.07610.1016/j.bbrc.2020.09.076 ↗
3. 10.1021/acsnano.2c0534110.1021/acsnano.2c05341 ↗
4. 10.1039/D1BM01280K10.1039/D1BM01280K ↗
5. 10.1039/D1NR02159A10.1039/D1NR02159A ↗
6. 10.1039/C7NR07677K10.1039/C7NR07677K ↗
7. 10.1021/acsnano.6b0752510.1021/acsnano.6b07525 ↗
8. 10.1002/anie.20191504010.1002/anie.201915040 ↗
9. 10.1016/j.jpba.2021.11419910.1016/j.jpba.2021.114199 ↗
10. 10.1021/acsmacrolett.1c0018310.1021/acsmacrolett.1c00183 ↗
11. 10.1186/s12951-023-01939-710.1186/s12951-023-01939-7 ↗
12. 10.21037/jtd.2017.12.10610.21037/jtd.2017.12.106 ↗
13. 10.1016/j.aquatox.2020.10546610.1016/j.aquatox.2020.105466 ↗
14. 10.1021/acscentsci.0c0158610.1021/acscentsci.0c01586 ↗
15. 10.1002/adma.20210450410.1002/adma.202104504 ↗
16. 10.1007/s40820-021-00761-w10.1007/s40820-021-00761-w ↗
17. 10.1186/s12951-021-01013-010.1186/s12951-021-01013-0 ↗
18. 10.1002/anie.20200873210.1002/anie.202008732 ↗
19. 10.1021/acsnano.2c0537910.1021/acsnano.2c05379 ↗
20. 10.1016/j.matt.2020.10.00210.1016/j.matt.2020.10.002 ↗
21. 10.1021/acsapm.2c0022810.1021/acsapm.2c00228 ↗
22. 10.1021/acsbiomaterials.0c0012510.1021/acsbiomaterials.0c00125 ↗
23. 10.1021/acsabm.1c0046710.1021/acsabm.1c00467 ↗
24. 10.1021/acs.biomac.1c0115210.1021/acs.biomac.1c01152 ↗
25. 10.1016/j.biomaterials.2021.12084710.1016/j.biomaterials.2021.120847 ↗
26. 10.1021/acs.nanolett.1c0048810.1021/acs.nanolett.1c00488 ↗
27. 10.1259/bjr.2013067610.1259/bjr.20130676 ↗
28. 10.1016/j.biomaterials.2023.12209410.1016/j.biomaterials.2023.122094 ↗
29. 10.1002/EXP.2021013410.1002/EXP.20210134 ↗
30. 10.1113/EP08908510.1113/EP089085 ↗
31. 10.1152/ajprenal.00334.201510.1152/ajprenal.00334.2015 ↗
32. 10.1021/acsmaterialslett.3c0045110.1021/acsmaterialslett.3c00451 ↗
33. 10.1002/cbic.20210009810.1002/cbic.202100098 ↗
34. 10.1002/advs.20200292710.1002/advs.202002927 ↗
35. 10.1002/adma.20210039810.1002/adma.202100398 ↗
36. 10.1002/adma.20200748810.1002/adma.202007488 ↗
37. 10.1002/EXP.2023002710.1002/EXP.20230027 ↗
38. 10.1016/j.apsb.2023.10.00610.1016/j.apsb.2023.10.006 ↗
39. 10.1002/anie.20220616910.1002/anie.202206169 ↗
40. 10.1021/acsmaterialslett.0c0000210.1021/acsmaterialslett.0c00002 ↗
41. 10.1021/acsnano.3c0471810.1021/acsnano.3c04718 ↗